☆ 4.6 Editorial Material

Aducanumab produced a clinically meaningful benefit in association with amyloid lowering

ALZHEIMERS RESEARCH & THERAPY (2021)

Get Full Text
Add to Collection

Journal

ALZHEIMERS RESEARCH & THERAPY
Volume 13, Issue 1, Pages -

Publisher

BMC
DOI: 10.1186/s13195-021-00838-z

Keywords

Aducanumab; FDA; Clinical trials; Monoclonal antibodies; Lecanemab; Donanemab; Gantenerumab

Categories

Clinical Neurology Neurosciences

Funding

  1. NIGMS [P20GM109025]
  2. NIA [P20AG068053, R01AG053798, R35AG71476]
  3. NINDS [U01NS093334]

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.